You are here

  • Home
  • Archive
  • Volume 80, Issue 4
  • Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis

Article metrics

Article menu
Rheumatoid arthritis
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis

 

Online download statistics by month:

Online download statistics by month: November 2020 to April 2025

AbstractFullPdf
Nov 2020911887532
Dec 2020441428177
Jan 2021207199110
Feb 202117917384
Mar 2021891890244
Apr 2021438424174
May 2021263261131
Jun 202120920169
Jul 202118417952
Aug 202116916866
Sep 202125124672
Oct 202118518077
Nov 202115515277
Dec 202110610948
Jan 202214314450
Feb 2022888932
Mar 202210910450
Apr 202214615258
May 202214113741
Jun 202211811341
Jul 202211311044
Aug 202212612749
Sep 202212212249
Oct 202211411456
Nov 20221139951
Dec 2022777428
Jan 2023474529
Feb 2023918629
Mar 2023868041
Apr 2023725861
May 2023655738
Jun 2023605533
Jul 20231009690
Aug 202310910447
Sep 2023555117
Oct 2023534840
Nov 2023847332
Dec 2023866530
Jan 20241258842
Feb 2024675335
Mar 2024928595
Apr 2024938061
May 2024796833
Jun 2024767228
Jul 2024434024
Aug 2024574929
Sep 2024686442
Oct 2024948522
Nov 2024636431
Dec 2024636118
Jan 2025747124
Feb 2025807923
Mar 2025313126
Apr 2025292923
Total804177193505